Paradigm Asset Management Co. LLC increased its position in Illumina, Inc. (NASDAQ:ILMN) by 5.6% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 950 shares of the life sciences company’s stock after buying an additional 50 shares during the period. Paradigm Asset Management Co. LLC’s holdings in Illumina were worth $165,000 as of its most recent filing with the SEC.

Several other institutional investors also recently made changes to their positions in the company. Meiji Yasuda Asset Management Co Ltd. boosted its position in shares of Illumina by 52.0% in the second quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,895 shares of the life sciences company’s stock worth $502,000 after buying an additional 990 shares during the period. American Century Companies Inc. boosted its position in shares of Illumina by 276.9% in the second quarter. American Century Companies Inc. now owns 475,111 shares of the life sciences company’s stock worth $82,441,000 after buying an additional 349,058 shares during the period. Sumitomo Mitsui Trust Holdings Inc. boosted its position in shares of Illumina by 2.1% in the second quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 414,826 shares of the life sciences company’s stock worth $71,981,000 after buying an additional 8,570 shares during the period. Federated Investors Inc. PA boosted its position in shares of Illumina by 46.2% in the second quarter. Federated Investors Inc. PA now owns 3,704 shares of the life sciences company’s stock worth $642,000 after buying an additional 1,171 shares during the period. Finally, Columbus Circle Investors boosted its position in shares of Illumina by 46.3% in the second quarter. Columbus Circle Investors now owns 86,768 shares of the life sciences company’s stock worth $15,056,000 after buying an additional 27,456 shares during the period. Hedge funds and other institutional investors own 93.32% of the company’s stock.

Illumina, Inc. (NASDAQ:ILMN) opened at 195.94 on Wednesday. The company has a market capitalization of $28.61 billion, a price-to-earnings ratio of 39.31 and a beta of 0.83. The stock has a 50 day moving average price of $183.92 and a 200 day moving average price of $176.00. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $199.95.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Tuesday, August 1st. The life sciences company reported $0.82 earnings per share for the quarter, topping analysts’ consensus estimates of $0.68 by $0.14. Illumina had a net margin of 30.27% and a return on equity of 19.69%. The firm had revenue of $662 million during the quarter, compared to analysts’ expectations of $642.38 million. During the same period in the prior year, the company earned $0.86 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. On average, equities analysts expect that Illumina, Inc. will post $3.65 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This news story was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/08/30/paradigm-asset-management-co-llc-buys-50-shares-of-illumina-inc-ilmn.html.

A number of brokerages have recently commented on ILMN. BidaskClub cut Illumina from a “hold” rating to a “sell” rating in a report on Thursday, August 17th. Barclays PLC restated an “equal weight” rating and set a $150.00 price objective on shares of Illumina in a report on Wednesday, August 9th. Vetr upgraded Illumina from a “hold” rating to a “buy” rating and set a $209.78 price objective for the company in a report on Wednesday, August 9th. Canaccord Genuity upgraded Illumina from a “hold” rating to a “buy” rating and boosted their price objective for the company from $170.00 to $215.00 in a report on Monday, August 7th. Finally, Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Three research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $177.01.

In other Illumina news, SVP Mostafa Ronaghi sold 10,000 shares of the company’s stock in a transaction dated Wednesday, August 2nd. The shares were sold at an average price of $195.00, for a total value of $1,950,000.00. Following the completion of the transaction, the senior vice president now directly owns 76,585 shares of the company’s stock, valued at approximately $14,934,075. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $184.75, for a total transaction of $26,788.75. Following the completion of the transaction, the senior vice president now directly owns 10,791 shares of the company’s stock, valued at $1,993,637.25. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 138,185 shares of company stock valued at $25,063,480. 1.60% of the stock is owned by corporate insiders.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Stock Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related stocks with our FREE daily email newsletter.